Published in J Exp Med on September 01, 1976
Induction of in vitro differentiation and immunoglobulin synthesis of human leukemic B lymphocytes. J Exp Med (1978) 2.39
Human lymphocyte antigens: production of a monoclonal antibody that defines functional thymus-derived lymphocyte subsets. Proc Natl Acad Sci U S A (1979) 2.07
Polyclonal activation of bone-marrow-derived lymphocytes from human peripheral blood measured by a direct plaque-forming cell assay. Proc Natl Acad Sci U S A (1976) 1.80
Antigen-induced in vitro antibody production in humans: a model for B cell activation and immunoregulation. Proc Natl Acad Sci U S A (1981) 1.80
Immunoregulation in humans: control of antitetanus toxoid antibody production after booster immunization. J Clin Invest (1978) 1.70
Pokeweed mitogen induced differentiation of human B cells: evaluation by a protein A haemolytic plaque assay. Immunology (1979) 1.39
Endotoxin protein is a mitogen and polyclonal activator of human B lymphocytes. J Exp Med (1979) 1.26
Inhibition of polyclonal B-cell activation by suppressor monocytes in patients with sarcoidosis. Clin Exp Immunol (1978) 1.25
Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B-cell activation. Immunology (1980) 1.24
Humoral immunity in leprosy: immunoglobulin G and M antibody responses to Mycobacterium leprae in relation to various disease patterns. Infect Immun (1982) 1.19
Antigen-specific induction and regulation of antibody synthesis in cultures of human peripheral blood mononuclear cells. Proc Natl Acad Sci U S A (1980) 1.13
Suppressive effect on polyclonal B-cell activation of a synthetic peptide homologous to a transmembrane component of oncogenic retroviruses. Proc Natl Acad Sci U S A (1987) 1.13
Human T-lymphocyte response in vitro to synthetic peptides of herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A (1985) 1.12
Use of a human plaque-forming cell assay to study peripheral blood bursa-equivalent cell activation and excessive suppressor cell activity in humoral immunodeficiency. J Clin Invest (1979) 1.11
Immunoregulation of the in vitro anti-HBs antibody synthesis in chronic HBsAg carriers and in recently boosted anti-hepatitis B vaccine recipients. Clin Exp Immunol (1985) 1.10
Activation of human B lymphocytes. VIII. Differential radiosensitivity of subpopulations of lymphoid cells involved in the polyclonally-induced PFC responses of peripheral blood B lymphocytes. Immunology (1978) 1.10
In vitro generation of antigen-specific hemolytic plaque-forming cells from human peripheral blood mononuclear cells. J Exp Med (1981) 1.08
Polyclonal activation of human peripheral blood B lymphocytes by formaldehyde-fixed Salmonella paratyphi B. I. Immunoglobulin production without DNA synthesis. J Exp Med (1981) 1.05
Evidence for the synthesis and release of strongly immunosuppressive, noncytotoxic substances by Streptococcus intermedius. J Clin Invest (1979) 1.01
Corticosteroid enhancement of immunoglobulin synthesis by pokeweed mitogen-stimulated human lymphocytes. Clin Exp Immunol (1979) 0.97
Depressed primary in vitro antibody response in rheumatoid arthritis. Clin Exp Immunol (1979) 0.97
Spontaneous antibody-secreting human blood lymphocytes detected with a protein A plaque assay. Clin Exp Immunol (1980) 0.96
In vitro idiotypic suppression of chronic lymphocytic leukemia lymphocytes secreting monoclonal immunoglobulin M anti-sheep erythrocyte antibody. J Clin Invest (1980) 0.95
Polyclonal activation to immunoglobulin secretion in human adenoid lymphocytes induced by bacteria from nasopharynx in vitro. Clin Exp Immunol (1978) 0.93
Clinical evaluation of B cell and T-regulator cell function using a protein A haemolytic plaque assay. Clin Exp Immunol (1981) 0.92
Specific in vivo and in vitro antibody response to tetanus toxoid immunization. Clin Exp Immunol (1982) 0.90
Plaque-forming cells in human cord blood: studies on T and B cell function. Clin Exp Immunol (1980) 0.90
T-cell regulation of polyclonal B-cell activation induced by extracts of oral bacteria associated with periodontal diseases. Infect Immun (1984) 0.88
Fractionation and characterization of the immunosuppressive substance in crude extracellular products released by Streptococcus intermedius. J Clin Invest (1981) 0.88
Comparison of the relative cytotoxic effector cell capabilities and the proportions of cells bearing various surface markers in human tonsil and peripheral blood mononuclear cells. Clin Exp Immunol (1978) 0.88
Functional studies of rabbit T lymphocytes. Immunology (1981) 0.87
Severe combined immunodeficiency disease: a model of T-cell dysfunction. Clin Exp Immunol (1978) 0.87
Tuberculin purified protein derivative-reactive T cells in cord blood lymphocytes. Infect Immun (1981) 0.87
Mitogenicity of Mycoplasma fermentans for human lymphocytes. Infect Immun (1978) 0.87
Polyclonal human T lymphocyte activation results in the secondary functional activation of the human B lymphocyte. Clin Exp Immunol (1981) 0.86
Bacterial lipopolysaccharide-induced immunoglobulin synthesis by human blood lymphocytes partially depleted of monocytes. Clin Exp Immunol (1982) 0.86
Functional activity of peripheral mononuclear cells in cystic fibrosis: antibodies and plaque formation. Clin Exp Immunol (1982) 0.82
Specific in vitro antimannan-rich antigen of Candida albicans antibody production by sensitized human blood lymphocytes. J Clin Invest (1983) 0.82
The effects of CP 17193, an immunosuppressive pyrazaloquinoline, on the development of spontaneous lupus disease in NZBW F1 hybrid mice. Clin Exp Immunol (1992) 0.82
Human B cell function in responder and non-responder individuals. II. The role of T helper cells in promoting the PWM-induced B cell production of immunoprotein. Clin Exp Immunol (1983) 0.78
Studies on a new lymphocyte mitogen from Bordetella pertussis. I. Induction of proliferation and polyclonal antibody formation. J Exp Med (1981) 0.76
Antibody-dependent cellular cytotoxicity mediated by subpopulations of human T lymphocytes: killing of human erythrocytes and autologous lymphoid cells. Immunology (1980) 0.75
Induction of suppressor cells after activation of human peripheral blood mononuclear cells with sodium periodate. Immunology (1982) 0.75
Limiting dilution analysis of specific in vitro anti-herpes simplex virus antibody production by human lymphocytes. Clin Exp Immunol (1987) 0.75
Influence of TPA (12-O-tetradodecanoyl-phorbol-13-acetate) on human B lymphocyte function. Clin Exp Immunol (1985) 0.75
Immunization of dissociated spleen cell cultures from normal mice. J Exp Med (1967) 30.93
Antitrinitrophenyl (TNP) plaque assay. Primary response of Balb/c mice to soluble and particulate immunogen. Proc Soc Exp Biol Med (1969) 18.89
Plaque formation in agar by single antibody-producing cells. Science (1963) 17.94
The regulatory influence of activated T cells on B cell responses to antigen. Adv Immunol (1972) 9.43
The mitogenic effects of endotoxin and staphylococcal enterotoxin B on mouse spleen cells and human peripheral lymphocytes. J Immunol (1970) 4.62
Plaque forming cells: methodology and theory. Transplant Rev (1974) 3.92
Functional analysis of murine and human B lymphocyte subsets. Transplant Rev (1975) 3.69
Nonspecificity of the limulus amebocyte lysate test: positive reactions with polynucleotides and proteins. J Infect Dis (1973) 3.40
Selective triggering of human T and B lymphocytes in vitro by polyclonal mitogens. J Exp Med (1974) 3.39
Thymus-independent B-cell induction and paralysis. Adv Immunol (1975) 3.27
Alternate-day prednisone therapy and human lymphocyte subpopulations. J Clin Invest (1975) 2.10
Purified protein derivative of tuberculin induces immunoglobulin production in normal mouse spleen cells. J Exp Med (1973) 1.98
Molecular basis of B-cell activation. I. Mitogenicity of native and substituted dextrans. Scand J Immunol (1974) 1.87
Differentiation of B cells: sequential appearance of responsiveness to polyclonal activators. Scand J Immunol (1974) 1.57
In vitro antibody formation by human tonsil lymphocytes. J Immunol (1974) 1.47
In vitro induction and measurement of hemolytic plaque forming cells in man. J Immunol Methods (1976) 1.42
Artifactual plaque formation in vitro and in vivo to passive transfer of specific antibody. J Immunol (1976) 1.36
Role of C'3 and Fc receptors in B-lymphocyte activation. J Exp Med (1975) 1.30
Production of antibody to sheep red blood cells by human tonsil cells in vitro. Nature (1973) 1.28
B-cell mitogenic effects on human lymphocytes of rabbit anti-human beta 2-microglobulin. Scand J Immunol (1975) 1.27
Responsiveness of lymphoid precursors to polyclonal B-cell activators. Scand J Immunol (1975) 1.08
HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (1993) 15.54
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med (1992) 13.29
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science (1986) 11.74
Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med (1983) 10.09
Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med (1986) 9.86
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum (1990) 8.92
The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum (1990) 8.67
The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum (1990) 8.36
Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med (1983) 8.26
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum (1990) 8.23
The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science (1989) 7.90
Toward an understanding of the correlates of protective immunity to HIV infection. Science (1996) 7.59
Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science (1987) 7.22
The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med (1978) 7.17
Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med (1986) 6.52
Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med (1985) 6.46
NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med (1984) 6.45
Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci U S A (1989) 6.32
Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A (1989) 6.32
Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol (1989) 6.02
Takayasu arteritis. Ann Intern Med (1994) 5.94
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med (1993) 5.32
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol (1986) 5.19
Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med (1976) 5.16
Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus. J Virol (1986) 5.05
The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest (1974) 4.90
Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) (1973) 4.89
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med (2000) 4.83
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Human immunodeficiency virus infection among patients attending clinics for sexually transmitted diseases. N Engl J Med (1988) 4.81
Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci U S A (1990) 4.80
Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med (1996) 4.72
NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med (1982) 4.70
The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum (1990) 4.43
Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A (1991) 4.23
HIV. An elusive soluble suppressor. Nature (1995) 4.18
Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81
Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. Science (1986) 3.80
Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol (1997) 3.79
The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol (1997) 3.77
Re-emergence of HIV after stopping therapy. Nature (1999) 3.54
AIDS--an immunologic reevaluation. N Engl J Med (1984) 3.53
Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature (1990) 3.50
Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J Immunol (1988) 3.45
Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science (1989) 3.43
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis (1997) 3.35
Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood (1988) 3.30
Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol (1986) 3.29
Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science (1984) 3.20
Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol (1985) 3.19
Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci U S A (1990) 3.18
Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis (1991) 3.16
Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. J Immunol (1986) 3.12
Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med (1998) 3.11
Immunoregulatory aberrations in systemic lupus erythematosus. J Immunol (1978) 3.07
Bacteremia due to Mycobacterium avium-intracellulare in the acquired immunodeficiency syndrome. Ann Intern Med (1983) 3.06
Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol (1981) 3.02
Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci U S A (1999) 3.00
Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature (1997) 2.94
Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med (1989) 2.94
Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science (1994) 2.92
The cardiovascular manifestations of the hypereosinophilic syndrome. Prospective study of 26 patients, with review of the literature. Am J Med (1979) 2.86
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol (1996) 2.86
Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J Virol (1987) 2.84
Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis (1996) 2.84
Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med (1990) 2.82
Immunopathogenesis of the acquired immunodeficiency syndrome. Ann Intern Med (1985) 2.77
NIH conference. The acquired immunodeficiency syndrome: an update. Ann Intern Med (1985) 2.68
Increasing viral burden in CD4+ T cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease. Ann Intern Med (1990) 2.65
Integrated proviral human immunodeficiency virus type 1 is present in CD4+ peripheral blood lymphocytes in healthy seropositive individuals. J Virol (1989) 2.62
Death in the AIDS patient: role of cytomegalovirus. N Engl J Med (1983) 2.61
New concepts in the immunopathogenesis of HIV infection. Annu Rev Immunol (1995) 2.61
Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med (1996) 2.61
Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals. J Virol (1999) 2.58
Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus. Science (1986) 2.57
Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science (1988) 2.55
HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A (2001) 2.54
Separate signals for human B cell proliferation and differentiation in response to Staphylococcus aureus: evidence for a two-signal model of B cell activation. J Immunol (1982) 2.48
Bioterrorism: a clear and present danger. Nat Med (2001) 2.43
Intestinal infections in patients with the acquired immunodeficiency syndrome (AIDS). Etiology and response to therapy. Ann Intern Med (1988) 2.42
Effect of tumor necrosis factor alpha on mitogen-activated human B cells. J Exp Med (1987) 2.42
Mechanisms of corticosteroid action on lymphocyte subpopulations. I. Redistribution of circulating T and b lymphocytes to the bone marrow. Immunology (1975) 2.35
Differential sensitivity of human B cell subsets to activation signals delivered by anti-mu antibody and proliferative signals delivered by a monoclonal B cell growth factor. J Exp Med (1983) 2.34
Corticosteroid-mediated immunoregulation in man. Immunol Rev (1982) 2.34
The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum (1990) 2.32
Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest (1983) 2.32
Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis (1979) 2.31
Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med (1995) 2.31
Characterization of a monoclonal antibody (5E9) that defines a human cell surface antigen of cell activation. J Immunol (1981) 2.30
Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual. Proc Natl Acad Sci U S A (1988) 2.30
Three populations of cells with dendritic morphology exist in peripheral blood, only one of which is infectable with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1995) 2.26
The ocular manifestations of Wegener's granulomatosis. Fifteen years experience and review of the literature. Am J Med (1977) 2.26
Cogan syndrome: studies in thirteen patients, long-term follow-up, and a review of the literature. Medicine (Baltimore) (1980) 2.26